Boston Scientific spends $295M to snap up rest of cardiac ablation maker Farapulse

Boston Scientific will acquire the remaining shares of Farapulse for approximately $295 million, according to a Thursday announcement. The deal includes an additional $92 million in payments if certain clinical and regulatory milestones are hit as well as revenue-based payments for the next three years.